Circadian Technologies Limited (ASX: CIR) is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses.
 
Circadian owns an extensive portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating tumour blood supply. These programs are conducted through Vegenics Ltd, a wholly-owned subsidiary of Circadian.
Videos
Dec,2011 09:30 AM
Circadian’s continuing clinica..
19 Dec 2011 – Circadian Technologies Limited (ASX:CIR), CEO and managing director, Robert Klupacs, talks about applications for its VGX-100 therapy in the treatment of a range of solid tumours, its phase 1 and 2 clinical program and partnerships for commercialisation.
Circadian (ASX:CIR)
Company Directors
Mr Carlo Montagner (Non Exec. Director)
Mr Dominique Fisher (Chairman, Non Exec. Director)
Mr Don Clarke (Non Exec. Director)
DR. Errol Malta (Non Exec. Director)
Mr Robert Klupacs (Managing Director, CEO)
Ms Tina McMeckan (Non Exec. Director)
Contact Information
Phone: +61 3 9826 0399
Email:
Website:

Address
Level 1, 10 Wallace Avenue Toorak, Victoria, Australia, 3142
Media Releases
Circadian, Operational Achievements and Half-Year Financial Report 31 December 2011
20 Feb,2012 12:57 PM

In accordance with Listing Rule 4.2A, attached is the Half-Year Financial Report (reviewed) on the consolidated results of Circadian Technologies Limited (‘Circadian’ or ‘Group’) for the half-year ended 31 December 2011. Previous corresponding period is the financial year ended 30 June 2011 and the half year ended 31 December 2010.

Results for the period predominantly reflect the Group’s investment in advancing its cancer treatment programs VGX-100, VGX-200 and VGX-300. The development, including associated costs, of the VEGFR3 antibody as a cancer treatment, licensed to ImClone Inc (owned by Eli Lilly, NYSE:LLY) and the Cancers of Unknown Primaries (CUP) diagnostic, licensed to Healthscope Limited (ASX:HSP), are being undertaken by those respective licensees.

An analysis of the financial results is provided in the attached Appendix 4D Half-Year Financial Report.

For details regarding Circadian’s half-year results and operational highlights/events refer to the Half-Year Financial Report attached.

This letter and the attached Half-Year Financial Report form part of this announcement to the Australian Stock Exchange Limited, and should be read in conjunction with the Company’s Annual Report for the year ended 30 June 2011.


To view full Report please download PDF below: